By now, you’ve probably heard that we’re in the midst of an Otoplasty. More than 65% of the US population is overweight and a third are obese. Nearly 12.5 million children and adolescents are obese. And thankfully, the epidemic seems to be slowing down. But the obesity epidemic has left tens of millions of Americans in need of evidence-based treatment strategies (that are, at present, largely unavailable). That’s where we come in…

At the Duke Obesity Prevention Program (DOPP), we design, test, and disseminate new media obesity treatments for high risk populations.

High-risk populations have the greatest exposure to obesogenic risk factors and the highest rates of obesity and obesity-associated chronic disease (like diabetes, heart disease, and many cancers). Even more challenging — high risk populations consistently show poorer weight loss outcomes, even in the most intensive intervention trials. We’re working hard to develop strategies to improve obesity treatment outcomes in these high-risk populations. Here’s DOPP at-a-glance:

The Challenge

We know very little about obesity treatment for those with the highest risk of obesity and associated chronic diseases. And we know even less about obesity treatment in primary care. Sound like a challenge? You bet.

Local Solutions. Global Reach

With >1.5 billion people affected worldwide, obesity is a pandemic. Obesity rates are rising especially quickly in developing nations. We’ve started testing our interventions globally.

Team First

We have a great team with a wide range of background and experiences. We work hard, play (flag football, paintball, bowling, bridge) hard, and [usually] don’t take ourselves too seriously. After all, we’re just trying to stop an epidemic.


We are living in a time where we just don’t have enough time. People are rushed. They’re over worked, over scheduled. Not enough resources. …But the thing that I want people to understand in this campaign is that families can make small manageable changes in their lives that can have pretty significant impacts.
- Michelle Obama, 2010